Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid

Abstract

INTRODUCTIONTrisomy 21, or Down syndrome (DS), predisposes individuals to early‐onset Alzheimer's disease (AD). While monoclonal antibodies (mAbs) targeting amyloid are approved for older AD patients, their efficacy in DS remains unexplored. This study examines amyloid positron emission tomography (PET) positivity (A+), memory function, and clinical status across ages in DS to guide mAb trial designs.METHODSCross‐sectional data from the Alzheimer Biomarker Consortium–Down Syndrome (ABC‐DS) was analyzed. PET amyloid beta in Centiloids classified amyloid status using various cutoffs. Episodic memory was assessed using the modified Cued Recall Test, and clinical status was determined through consensus processes.RESULTSFour hundred nine DS adults (mean age = 44.83 years) were evaluated. A+ rates increased with age, with mean amyloid load rising significantly. Memory decline and cognitive impairment are also correlated with age.DISCUSSIONThese findings emphasize the necessity of tailoring mAb trials for DS, considering age‐related AD characteristics.HIGHLIGHTS There is rapid increase in prevalence of amyloid beta (Aβ) positron emission tomography (PET) positivity in Down syndrome (DS) after the age of 40 years. Aβ PET positivity thresholds have significant impact on prevalence rates in DS. There is a significant lag between Aβ PET positivity and clinical symptom onset in DS.